The global pharmaceutical industry experienced 0.67% rise in new job postings related to big data in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares with a 0.67% rise in the previous quarter, and a 15% increase over Q3 20201.
Notably, General and Operations Managers jobs accounted for an 8% share of the global pharmaceutical industry’s big data-related total new job postings in Q3 2022, up 0.37% over the prior quarter.
Big data-related hiring activity is driven by Operations and General Managers
General and Operations Managers topped the list of top big data roles in the pharmaceutical industry. New job postings rose by 0.3% quarter-on-quarter. With a share at 7%, Software and Web Developers and Programmers came in second. New job postings increased by 10% in the third quarter.
Other prominent roles in big data include Biological Scientists, who have a 6% share of Q3 2022’s job postings, and Database and Network Administrators and Architects, who each have a 3% share.
Top five companies in the pharmaceutical industry account for 2% of all hiring activity
The top companies, in terms of number of new job postings tracked by GlobalData, as of Q3 2022 were Evolent Health , Johnson & Johnson, Intermountain Healthcare and Hastings Center. They combined accounted for 2% of all big-data-related active jobs within the pharmaceutical industry.
Evolent Health posted 2,137 jobs in Q3 2022 and registered a rise of 18% over the previous quarter, followed by Johnson & Johnson with 1,404 jobs and a 4% drop. Intermountain Healthcare, with 1,328 jobs, and Hastings Center, with 935 jobs, saw 0.3% growth and a 9.9% decrease, respectively. CVS Health, however, experienced a 4% drop with 804 job openings in Q3 2022.
US was the main driver of hiring activity, accounting for 78% percent of total job postings during Q3 2022
In Q3 2022 the US had 78% of the largest number of new jobs in big data in the pharmaceutical industry. India followed at 4% and 3% respectively. The US accounted for 3% more than the 75% it held in Q2 2022.